公开(公告)号：KR1020090090944A

公开(公告)日：2009-08-26

申请号：KR1020080016520

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  이은희 ,  최하림 ,  박아름 ,  김일수 ,  이화연

IPC: A61K38/16 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K48/00 ,  A61K2039/585 ,  C12N9/12

Abstract: A method for screening therapeutic agent or suppressing tumor by regulating Axl signal is provided to increase the sensitivity of natural killer cell by the expression of LIGHT gene and induce apoptosis of tumor cell. A composition for suppressing tumor comprises LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells) (TNFSF14) or its activator as an active ingredient. The activator is Axl receptor tyrosine kinase or its ligand. The Axl ligand is an antibody to Axl antibody, gamma-carboxylated Gas-6(growth-arrest specific gene 6) or protein S. The tumor is lymphatic tumor. A method for screening agent for suppressing or treating tumor comprises: a step of adding a test compound to a LIGHT (TNFSF14) or its activator; and a step of researching the influence of the test compound on the expression or activation of LIGHT or its activator.

Abstract translation: 提供通过调节Axl信号筛选治疗剂或抑制肿瘤的方法，以通过LIGHT基因的表达增加自然杀伤细胞的敏感性并诱导肿瘤细胞凋亡。 用于抑制肿瘤的组合物包括LIGHT（与蛋白D竞争结合于T细胞上的疱疹病毒进入介导蛋白的竞争性淋巴毒素样诱导蛋白）（TNFSF14）或其活化剂作为活性成分。 活化剂是Axl受体酪氨酸激酶或其配体。 Axl配体是Ax1抗体，γ-羧化气体-6（生长停滞特异性基因6）或蛋白S的抗体。肿瘤是淋巴瘤。 用于抑制或治疗肿瘤的筛选剂的方法包括：将测试化合物加入到LIGHT（TNFSF14）或其活化剂中的步骤; 以及研究化合物对LIGHT或其活化剂表达或活化的影响的一个步骤。

公开(公告)号：KR1020090090918A

公开(公告)日：2009-08-26

申请号：KR1020080016480

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  이은희 ,  박아름 ,  이화연 ,  이자운 ,  조영미

IPC: A61K38/16 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K38/005 ,  A61K48/00

Abstract: A composition for preventing and treating cervical cancer, which contains AxL receptor tyrosine kinase inhibitor is provided to regulate the expression of human papilloma virus (HPV) type 16 E6 gene and reduce the proliferation and metastatic property of cancer cell. A composition for preventing and treating cervical cancer comprises an inhibitor of Axl receptor tyrosine kinase as an active ingredient. A method for screening an agent for preventing and treating cervical cancer comprises: a step of adding a test compound to the Axl receptor tyrosine kinase; and a step of researching the influence of the test sample to the expression or activation of Axl and selecting a compound which suppresses the expression or activation of Axl.

Abstract translation: 提供含有AxL受体酪氨酸激酶抑制剂的宫颈癌预防和治疗组合物，用于调节人乳头状瘤病毒（HPV）16型E6基因的表达，降低癌细胞的增殖和转移性。 用于预防和治疗宫颈癌的组合物包含Ax1受体酪氨酸激酶的抑制剂作为活性成分。 用于筛选预防和治疗宫颈癌的药剂的方法包括：将测试化合物加入到Ax1受体酪氨酸激酶中的步骤; 研究测试样品对Axl的表达或活化的影响并选择抑制Ax1表达或激活的化合物的步骤。